Shared Genetic Architecture and Causal Relationship Between Serum 25-Hydroxyvitamin D and Bone Mineral Density - Takeaways - MDSpire

Shared Genetic Architecture and Causal Relationship Between Serum 25-Hydroxyvitamin D and Bone Mineral Density

  • By

  • Linna Sha

  • Li Zhang

  • Xunying Zhao

  • Rong Xiang

  • Xueyao Wu

  • Jiangbo Zhu

  • Jiaojiao Hou

  • Qin Deng

  • Chenjiarui Qin

  • Changfeng Xiao

  • Yang Qu

  • Tao Han

  • Jinyu Zhou

  • Sirui Zheng

  • Ting Yu

  • Xin Song

  • Bin Yang

  • Mengyu Fan

  • Xia Jiang

  • October 21, 2024

  • 0 min

Share

  • 1

    This study investigates the genetic overlap and causal links between serum 25-hydroxyvitamin D levels and bone mineral density.

  • 2

    No global genetic correlation was found between serum 25OHD and bone mineral density, but a significant local signal was identified.

  • 3

    Mendelian randomization indicated no causal association in the overall population, but positive effects were noted in males and older individuals.

  • 4

    A total of 49 pleiotropic single-nucleotide variations were identified, including four novel SNVs related to serum 25OHD and bone mineral density.

  • 5

    The findings suggest potential health benefits of increasing serum 25OHD levels to reduce osteoporosis risk, particularly in men and older adults.

Original Source(s)

Shared Genetic Architecture and Causal Relationship Between Serum 25-Hydroxyvitamin D and Bone Mineral Density

  • by Linna Sha, Li Zhang, Xunying Zhao, Rong Xiang, Xueyao Wu, Jiangbo Zhu, Jiaojiao Hou, Qin Deng, Chenjiarui Qin, Changfeng Xiao, Yang Qu, Tao Han, Jinyu Zhou, Sirui Zheng, Ting Yu, Xin Song, Bin Yang, Mengyu Fan, Xia Jiang

  • October 21, 2024

Related Content

Raman spectroscopic fingerprinting uncovers a multi-scale structural–mechanical–transcriptomic coupling landscape in osteoporosis

Correction: Fracture and mortality outcomes by osteoporosis treatment route in patients with type 2 diabetes and obesity: a propensity-matched registry study

Predicting poor response to anti-osteoporosis therapy: a machine learning model integrating clinical and novel biomarker data